Glaucoma Drug-Delivery Implants
Tiny implants that release glaucoma medication steadily for months at a time, a way to control eye pressure without the daily burden of drops.
Why Drug-Delivery Implants Matter
For decades, medical treatment of glaucoma has meant daily eye drops. Drops work well, but only if they are used correctly, every day, on schedule, for life. Studies consistently show that many patients miss doses, run out, struggle with the bottle, or simply forget, and inconsistent dosing is one of the leading reasons glaucoma quietly progresses despite treatment.
Implantable and sustained-release drug-delivery devices solve this problem at its root. Instead of relying on a drop reaching the eye each day, a tiny implant is placed in or on the eye and releases medication steadily for months at a time. The result is consistent, around-the-clock pressure control without the daily burden, and without the surface irritation and preservative exposure that long-term drops can cause. This is one of the most exciting frontiers in glaucoma care, and several devices are already FDA-approved and in use today.
FDA-Approved Intracameral Implants
Two drug implants are FDA-approved for open-angle glaucoma and ocular hypertension. Both are placed inside the front chamber of the eye (the term is "intracameral") during a quick, painless in-office procedure, and both release a prostaglandin medication, the same family as the most common glaucoma drops, directly where it is needed.
Durysta (bimatoprost implant)
Durysta is a tiny, fully biodegradable implant, smaller than a grain of rice, that is injected into the front chamber of the eye. It is made of a solid polymer matrix that slowly dissolves, releasing the medication bimatoprost steadily over several months. In clinical studies, a single Durysta implant lowered eye pressure by roughly 5 to 8 mmHg (about 30 percent), comparable to a daily prostaglandin drop, and because the implant dissolves completely, nothing needs to be removed.
At present, Durysta is approved for a single administration per eye, because studies of repeated dosing found a risk of effects on the cornea's inner cell layer. It is often an excellent option for a patient who wants a break from drops, who is about to have other eye surgery, or who is struggling with drop compliance.
iDose TR (travoprost implant)
iDose TR takes a different approach. Rather than dissolving, it is a miniature titanium reservoir, roughly the size of an eyelash tip, that is inserted through a tiny corneal incision and gently anchored into the eye's drainage angle (the trabecular meshwork). From there it releases the medication travoprost continuously. In the pivotal trials, iDose TR controlled eye pressure as effectively as timolol eye drops through 12 months, with the great majority of patients staying off their drops during that time.
Because iDose TR is anchored rather than free-floating and does not biodegrade, it can be exchanged for a fresh implant when it is eventually depleted. For the right patient, it offers the prospect of continuous, drop-free pressure control that can be renewed over time.
Next-Generation and Emerging Devices
The field is moving quickly. Several newer implants aim to last even longer, dissolve on their own, or combine drug delivery with cataract surgery. These represent the near future of glaucoma care, and understanding them helps you have an informed conversation about your options.
iDose TREX (extended-release travoprost)
The next-generation version of iDose TR, designed with nearly double the drug capacity for a longer duration of effect between exchanges. It builds directly on the proven iDose platform with the goal of even fewer procedures over a patient's lifetime.
OTX-TIC (biodegradable travoprost implant)
An investigational implant that combines the best of both approved devices: like Durysta it fully biodegrades so nothing remains, and like iDose it sits in the drainage angle. Built on a hydrogel platform loaded with travoprost, it has shown meaningful pressure reduction from a single implant lasting several months in clinical trials.
Spyglass drug-eluting lens implant
A genuinely novel idea for patients who also need cataract surgery: a standard artificial lens implant fitted with medication-eluting pads that release a glaucoma drug from inside the eye for a targeted duration of up to three years. Because it is placed during routine cataract surgery, it would treat the cataract and deliver glaucoma medication in a single step. It remains investigational, with encouraging early trial data.
Surface and Punctal Sustained-Release Options
Not every sustained-release device is placed inside the eye. Two other approaches deliver medication from the eye's surface, avoiding any intraocular procedure. These are largely investigational but worth knowing about.
Bimatoprost ocular ring
A soft, flexible ring that rests under the eyelids in the conjunctival pocket, much like a large contact lens sitting out of view. It slowly releases bimatoprost and can be replaced periodically. It requires no incision and no daily drops, and it can be removed at any time.
Punctal-plug drug delivery
Tiny plugs placed in the eye's tear-drainage openings (the puncta) can be loaded with a glaucoma medication such as latanoprost or travoprost, releasing it into the tear film over weeks to a few months. This approach is convenient and completely non-surgical, though keeping the plug reliably in place has been the main challenge in trials.
Is a Drug-Delivery Implant Right for You?
Sustained-release implants are especially valuable for patients who find daily drops difficult, whether from arthritis, memory, cost, travel, or simply the fatigue of lifelong dosing, and for those whose eyes are irritated by drop preservatives. They can be used on their own, or alongside SLT laser, MIGS, or other treatments as part of a complete plan.
They are not right for every eye. The best choice depends on your type and severity of glaucoma, the health of your cornea and drainage angle, whether you are also having cataract surgery, and your personal goals. As a dedicated glaucoma practice, we stay current with every approved and emerging option, and we can talk through whether a drug-delivery implant fits your situation.
The bottom line: drug-delivery implants are changing what glaucoma treatment looks like, replacing the daily drop with steady, hands-off pressure control. If keeping up with drops has been a struggle, ask whether an implant such as Durysta or iDose TR could be a fit. Explore the rest of our treatment options to see how these devices fit into the full range of care.
Frequently Asked Questions
What is a glaucoma drug-delivery implant?
It is a very small device placed in or on the eye that releases glaucoma medication continuously over months, so eye pressure stays controlled without daily eye drops. Two implants, Durysta and iDose TR, are FDA-approved, and several more are in development.
How is a drug implant different from eye drops?
Both deliver the same kinds of pressure-lowering medication. The difference is consistency and convenience: a drop must be put in correctly every single day, while an implant delivers a steady dose automatically for months, removing the risk of missed doses and avoiding daily preservative exposure on the eye surface.
Does getting the implant hurt?
No. The eye is numbed first, and the FDA-approved intracameral implants (Durysta and iDose TR) are placed during a quick, painless in-office procedure through a tiny opening. Most patients feel only mild pressure and return to normal activities promptly.
How long does a glaucoma implant last?
It depends on the device. Durysta releases medication over several months and then fully dissolves. iDose TR is designed to deliver medication for about a year and can be exchanged for a fresh implant. Newer devices aim for even longer durations.
Can I still use drops or have other treatment with an implant?
Yes. Drug-delivery implants can be used alone or combined with other treatments such as SLT laser, MIGS, or additional drops as part of a complete, individualized glaucoma plan.
Who is a good candidate for a drug-delivery implant?
Patients who struggle with daily drops, whether from arthritis, forgetfulness, cost, or eye-surface irritation, and those who want steadier pressure control are often excellent candidates. The final decision depends on your glaucoma type, corneal and drainage-angle health, and personal goals.
See a glaucoma specialist. Dr. Robert Gunzenhauser is Harvard-educated and UCLA fellowship-trained in glaucoma, providing expert diagnosis and treatment for Glaucoma Drug-Delivery Implants at Inland Glaucoma Center in Upland, CA.